As GLP-1 receptor agonists have gained popularity for weight management, a growing number of individuals are facing the reality of discontinuation. The reasons for discontinuation include, but are not limited to cost, side effects, supply issues, or, in successful cases, achieving weight goals. However, the transition off GLP-1 medications is not simple and generally requires a multi-disciplinary approach. Without significant lifestyle modifications with the assistance of qualified professionals (i.e. Registered Dietitians) to maintain the positive outcomes, the weight regain rate is high – one meta-analysis stating around 50-60% of individuals regained lost weight within one year.1 This is particularly concerning because the composition of weight loss is not just fat, but also lean muscle tissue. Estimates are between 20-40% of weight loss is from lean muscle mass.2 Meaning, weight regain is likely all fat tissue, and individuals with weight regain are becoming more obese by proportion. Utilizing the clinical expertise of a Registered Dietitian during this metabolic transition can help limit weight regain and preserve lean muscle mass by implementing a diet that prioritizes slow-digesting foods, specifically proteins to maintain the feeling of fullness that the GLP-1’s provided.
The Growing GLP-1 Market and User Base
The GLP-1 medication market has experienced unprecedented growth, with current estimates suggesting that over roughly 12% of Americans have used or are currently using GLP-1s.3 This number represents a dramatic increase from just 1 million users in 2019, highlighting the rapid adoption of these drugs for both diabetes management and weight loss.4
Market analysts project this number could reach 25-30 million users by 2030, driven by expanding insurance coverage, increased awareness, and the development of new formulations. However, this growth also means that millions of individuals may eventually face the challenge of discontinuing these medications, making transition strategies increasingly important.
Understanding GLP-1’s Mechanism of Action
GLP-1 medications work by mimicking the hormone glucagon-like peptide-1, which naturally regulates blood sugar and appetite.1 These drugs slow gastric emptying, meaning food stays in the stomach longer, creating prolonged satiety. They also affect the brain’s appetite centers, reducing food cravings and the desire to eat large portions. When individuals stop taking GLP-1 medications, these effects gradually diminish, often leading to increased appetite and the potential for weight regain. This is where strategic dietary choices become crucial.
The Case for Casein Protein
Casein protein has emerged as a valuable dietary tool for individuals transitioning off GLP-1 medications. Unlike the popular whey protein, which is rapidly absorbed, casein forms a gel-like clot in the stomach that significantly slows gastric emptying.5,6 It is well established that casein can remain in the stomach for 6-7 hours5 compared to whey’s 1-27 hours, providing sustained amino acid release and prolonged satiety signals. This extended gastric residence time can trigger the release of naturally occurring satiety hormones. For patients coming off a GLP-1 or its derivatives, incorporating casein protein with meals (or as a meal replacement) can help bridge the gap as their natural appetite regulation systems readjust. This strategic use of casein not only helps prevent the rapid weight regain commonly seen after GLP-1 cessation but also supports muscle protein synthesis during the transition period.
Casein protein represents a significantly underutilized opportunity in the protein market. Naturally occurring in milk at four times the concentration of whey, casein delivers a complete amino acid profile and, particularly in its micellar form, offers the same clean-label appeal that consumers demand.8 However, market research reveals that consumers consistently rate casein lower in perceived utility.8 This perception gap creates a compelling opportunity for the dairy industry to educate consumers about casein’s unique benefits, especially its superior performance in ready-to-drink applications. Casein demonstrates exceptional flavor stability and functional integrity in shelf-stable, low-acid protein beverages at neutral pH, making it ideally suited for the rapidly expanding RTD protein category.8 Most importantly, as millions of Americans transition off GLP-1 medications and seek natural ways to maintain satiety, casein’s slow-digesting properties and prolonged gastric residence time position it as the optimal protein choice for this emerging consumer segment. The convergence of RTD market growth and the post-GLP-1 transition trend presents casein with a unique positioning opportunity that could fundamentally reshape consumer perceptions and market share.
References
1. Tzang CC, Wu PH, Luo CA, Chen ZT, Lee YT, Huang ES, Kang YF, Lin WC, Tzang BS, Hsu TC. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. EClinicalMedicine. 2025 Nov 28;90:103680. doi: 10.1016/j.eclinm.2025.103680. PMID: 41399474; PMCID: PMC12702299.
2. Langer H, Gilmore N, Hayden C … Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans Cell Reports Medicine,
3. Harris E. Poll: Roughly 12% of US Adults Have Used a GLP-1 Drug, Even If Unaffordable. JAMA. 2024 Jul 2;332(1):8. doi: 10.1001/jama.2024.10333. PMID: 38848082.
4. BMJ 2024; 386 doi: https://doi.org/10.1136/bmj.q1645 (Published 23 July 2024)Cite this as: BMJ 2024;386:q1645
5. Kim J. Pre-sleep casein protein ingestion: new paradigm in post-exercise recovery nutrition. Phys Act Nutr. 2020 Jun 30;24(2):6-10. doi: 10.20463/pan.2020.0009. PMID: 32698256; PMCID: PMC7451833.
6. Mulet-Cabero, A., Torcello-Gómez, A., Saha, S., Mackie, A. R., Wilde, P. J., & Brodkorb, A. (2020). Impact of caseins and whey proteins ratio and lipid content on in vitro digestion and ex vivo absorption. Food Chemistry, 319, 126514. https://doi.org/10.1016/j.foodchem.2020.126514
7. Trommelen J, van Lieshout GAA, Nyakayiru J, Holwerda AM, Smeets JSJ, Hendriks FK, van Kranenburg JMX, Zorenc AH, Senden JM, Goessens JPB, Gijsen AP, van Loon LJC. The anabolic response to protein ingestion during recovery from exercise has no upper limit in magnitude and duration in vivo in humans. Cell Rep Med. 2023 Dec 19;4(12):101324. doi: 10.1016/j.xcrm.2023.101324. PMID: 38118410; PMCID: PMC10772463.
